Appears this posting was to announce the "critical
Post# of 153907
(Total Views: 490)
Posted On: 09/21/2021 2:07:09 PM
Appears this posting was to announce the "critically ill" trial is a go and remind us that the "moderate stage" trial was approved back on August 2nd.
It is a new approval for the critically ill trial.
This new clinical study will focus on hospitalized patients who are in a critical condition of COVID19, in need of mechanical and invasive ventilation or using Extracorporeal Membrane Oxygenation
(ECMO). It will be carried out in 22 research centers with 316 patients.
It is worth remembering that the clinical study for patients in the moderate stage of the disease,
already approved by the National Health Surveillance Agency – ANVISA, was subject of the Material
Fact published by the Company on August 2, 2021.
This new clinical trial, with critically ill patients, will also be conducted by the Academic Research
Organization (ARO) of the Hospital Israelita Albert Einstein (HIAE), in collaboration with CytoDyn,
the US company responsible for developing the drug, and BIOMM, exclusive partner for the
commercialization of leronlimab in Brazil.
The Company will keep its shareholders and the market in general updated on the subject of this
material fact.
Nova Lima/MG, September 21st, 2021.
Biomm S.A.
Mirna Santiago Vieira
Chief Financial and Investor Relations Office
It is a new approval for the critically ill trial.
This new clinical study will focus on hospitalized patients who are in a critical condition of COVID19, in need of mechanical and invasive ventilation or using Extracorporeal Membrane Oxygenation
(ECMO). It will be carried out in 22 research centers with 316 patients.
It is worth remembering that the clinical study for patients in the moderate stage of the disease,
already approved by the National Health Surveillance Agency – ANVISA, was subject of the Material
Fact published by the Company on August 2, 2021.
This new clinical trial, with critically ill patients, will also be conducted by the Academic Research
Organization (ARO) of the Hospital Israelita Albert Einstein (HIAE), in collaboration with CytoDyn,
the US company responsible for developing the drug, and BIOMM, exclusive partner for the
commercialization of leronlimab in Brazil.
The Company will keep its shareholders and the market in general updated on the subject of this
material fact.
Nova Lima/MG, September 21st, 2021.
Biomm S.A.
Mirna Santiago Vieira
Chief Financial and Investor Relations Office
(2)
(1)